DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes

Optimal HIV vaccines should elicit CD8+ T cells specific for HIV proteins presented on MHC class I products, because these T cells contribute to host resistance to viruses. We had previously found that the targeting of antigen to dendritic cells (DCs) in mice efficiently induces CD8+ T cell responses. To extend this finding to humans, we introduced the HIV p24 gag protein into a mAb that targets DEC-205/CD205, an endocytic receptor of DCs. We then assessed cross-presentation, which is the processing of nonreplicating internalized antigen onto MHC class I for recognition by CD8+ T cells. Low doses of αDEC-gag, but not control Ig-gag, stimulated proliferation and IFN-γ production by CD8+ T cells isolated from the blood of HIV-infected donors. αCD205 fusion mAb was more effective for cross-presentation than αCD209/DC-SIGN, another abundant DC uptake receptor. Presentation was diverse, because we identified eight different gag peptides that were recognized via DEC-205 in 11 individuals studied consecutively. Our results, based on humans with highly polymorphic MHC products, reveal that DCs and DEC-205 can cross-present several different peptides from a single protein. Because of the consistency in eliciting CD8+ T cell responses, these data support the testing of αDEC-205 fusion mAb as a protein-based vaccine.

[1]  R. Steinman,et al.  Differential Antigen Processing by Dendritic Cell Subsets in Vivo , 2007, Science.

[2]  P. Cresswell,et al.  A role for the endoplasmic reticulum protein retrotranslocation machinery during crosspresentation by dendritic cells. , 2006, Immunity.

[3]  G. Raposo,et al.  NOX2 Controls Phagosomal pH to Regulate Antigen Processing during Crosspresentation by Dendritic Cells , 2006, Cell.

[4]  G. Belz,et al.  The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[5]  R. Steinman,et al.  Intensified and protective CD4+ T cell immunity in mice with anti–dendritic cell HIV gag fusion antibody vaccine , 2006, The Journal of experimental medicine.

[6]  R. Steinman,et al.  Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses , 2006, The Journal of experimental medicine.

[7]  S. Grinstein,et al.  Quantitative and Dynamic Assessment of the Contribution of the ER to Phagosome Formation , 2005, Cell.

[8]  R. Steinman,et al.  Dendritic Cell-Specific Intercellular Adhesion Molecule 3-Grabbing Nonintegrin/CD209 Is Abundant on Macrophages in the Normal Human Lymph Node and Is Not Required for Dendritic Cell Stimulation of the Mixed Leukocyte Reaction1 , 2005, The Journal of Immunology.

[9]  D. Accapezzato,et al.  Chloroquine enhances human CD8+ T cell responses against soluble antigens in vivo , 2005, The Journal of experimental medicine.

[10]  S. Koyasu,et al.  Exogenous antigens are processed through the endoplasmic reticulum-associated degradation (ERAD) in cross-presentation by dendritic cells. , 2005, International immunology.

[11]  N. Letvin.  Progress toward an HIV vaccine. , 2005, Annual review of medicine.

[12]  M. Nowak,et al.  Determinants of Human Immunodeficiency Virus Type 1 Escape from the Primary CD8+ Cytotoxic T Lymphocyte Response , 2004, The Journal of experimental medicine.

[13]  Yao-Tseng Chen,et al.  IFN-gamma enables cross-presentation of exogenous protein antigen in human Langerhans cells by potentiating maturation. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[14]  B. Pulendran.  Modulating vaccine responses with dendritic cells and Toll‐like receptors , 2004, Immunological reviews.

[15]  D. Hanau,et al.  Dendritic cells cross-present HIV antigens from live as well as apoptotic infected CD4+ T lymphocytes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[16]  R. Steinman,et al.  In Vivo Targeting of Antigens to Maturing Dendritic Cells via the DEC-205 Receptor Improves T Cell Vaccination , 2004, The Journal of experimental medicine.

[17]  I. Mellman,et al.  Presentation of Exogenous Antigens on Major Histocompatibility Complex (MHC) Class I and MHC Class II Molecules Is Differentially Regulated during Dendritic Cell Maturation , 2003, The Journal of experimental medicine.

[18]  R. Dalton.  Natural history collections in crisis as funding is slashed , 2003, Nature.

[19]  M. Dhodapkar,et al.  T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Steffen Jung,et al.  In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. , 2002, Immunity.

[21]  J. Banchereau,et al.  How dendritic cells and microbes interact to elicit or subvert protective immune responses. , 2002, Current opinion in immunology.

[22]  R. Steinman,et al.  The CD8+ Dendritic Cell Subset Selectively Endocytoses Dying Cells in Culture and In Vivo , 2002, The Journal of experimental medicine.

[23]  C. Figdor,et al.  C-type lectin receptors on dendritic cells and langerhans cells , 2002, Nature Reviews Immunology.

[24]  M. Kaplan,et al.  Identification of HLA-A2–restricted CD8+ Cytotoxic T Cell Responses in Primary Biliary Cirrhosis , 2002, The Journal of Experimental Medicine.

[25]  M. Dhodapkar,et al.  Antitumor Monoclonal Antibodies Enhance Cross-Presentation of Cellular Antigens and the Generation of Myeloma-specific Killer T Cells by Dendritic Cells , 2002, The Journal of experimental medicine.

[26]  N. Bhardwaj,et al.  Efficiency of cross presentation of vaccinia virus‐derived antigens by human dendritic cells , 2001, European journal of immunology.

[27]  Michel C. Nussenzweig,et al.  Dendritic Cells Induce Peripheral T Cell Unresponsiveness under Steady State Conditions in Vivo , 2001, The Journal of experimental medicine.

[28]  M. Bevan,et al.  Cd8+ but Not Cd8− Dendritic Cells Cross-Prime Cytotoxic T Cells in Vivo , 2000, The Journal of experimental medicine.

[29]  J. Banchereau,et al.  Dendritic Cells Capture Killed Tumor Cells and Present Their Antigens to Elicit Tumor-Specific Immune Responses1 , 2000, The Journal of Immunology.

[30]  R. Steinman,et al.  A monoclonal antibody to the DEC-205 endocytosis receptor on human dendritic cells. , 2000, Human immunology.

[31]  Jonathan W. Yewdell,et al.  Rapid degradation of a large fraction of newly synthesized proteins by proteasomes , 2000, Nature.

[32]  Douglas S Kwon,et al.  DC-SIGN, a Dendritic Cell–Specific HIV-1-Binding Protein that Enhances trans-Infection of T Cells , 2000, Cell.

[33]  D. Montefiori,et al.  Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. , 1999, Science.

[34]  P. Ricciardi-Castagnoli,et al.  Fcγ Receptor–mediated Induction of Dendritic Cell Maturation and Major Histocompatibility Complex Class I–restricted Antigen Presentation after Immune Complex Internalization , 1999, The Journal of experimental medicine.

[35]  J. Yewdell,et al.  Mechanisms of exogenous antigen presentation by MHC class I molecules in vitro and in vivo: implications for generating CD8+ T cell responses to infectious agents, tumors, transplants, and vaccines. , 1999, Advances in immunology.

[36]  M. Albert,et al.  Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs , 1998, Nature.

[37]  B. Walker,et al.  β-Chemokines are released from HIV-1-specific cytolytic T-cell granules complexed to proteoglycans , 1998, Nature.

[38]  P. Klenerman,et al.  Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Xiping Wei,et al.  Antiviral pressure exerted by HIV-l-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus , 1997, Nature Medicine.

[40]  A. Prescott,et al.  Constitutive macropinocytosis allows TAP‐dependent major histocompatibility compex class I presentation of exogenous soluble antigen by bone marrow‐derived dendritic cells , 1997, European journal of immunology.

[41]  R P Johnson,et al.  Efficient lysis of human immunodeficiency virus type 1-infected cells by cytotoxic T lymphocytes , 1996, Journal of virology.

[42]  J. Miller,et al.  Constitutive class I-restricted exogenous presentation of self antigens in vivo , 1996, The Journal of experimental medicine.

[43]  U. Andersson,et al.  Antibody‐targeted superantigen therapy induces tumor‐infiltrating lymphocytes, excessive cytokine production, and apoptosis in human colon carcinoma , 1996, European journal of immunology.

[44]  S. Arya,et al.  Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells , 1995, Science.

[45]  C Danieli,et al.  Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products , 1995, The Journal of experimental medicine.

[46]  R. Steinman,et al.  Proliferating dendritic cell progenitors in human blood , 1994, The Journal of experimental medicine.

[47]  M. A. Saper,et al.  The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens , 1987, Nature.

[48]  J. Levy,et al.  CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. , 1986, Science.

[49]  J. Davey,et al.  Cytotoxic T cells recognize fragments of the influenza nucleoprotein , 1985, Cell.